Application of a bioinformatic pipeline to RNA-seq data identifies novel virus-like sequence in human blood

Marko Melnick 1,*, Patrick Gonzales 1, Thomas J. LaRocca 2, Yuping Song 3, Joanne Wuu 4, Michael Benatar 4, Björn Oskarsson 5, Leonard Petrucelli 3,6, Robin D. Dowell 7, Christopher D. Link 1,8 and Mercedes Prudencio 3,6,*

1Department of Integrative Physiology, University of Colorado, Boulder, CO 80303, USA
2Department of Health and Exercise Science, Center for Healthy Aging, Colorado State University, Fort Collins, CO 80523, USA
3Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA
4Department of Neurology, University of Miami, Miami, FL 33136, USA
5Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA
6Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, FL 32224, USA
7BioFrontiers Institute and Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, CO 80303, USA
8Institute for Behavioral Genetics, University of Colorado, Boulder, CO 80303, USA

*Corresponding authors. Department of Integrative Physiology, University of Colorado, 354 UCB, Boulder, CO 80303, USA. Email: marko.melnick@colorado.edu (M.M.) and Neuroscience Graduate Program, Mayo Clinic Graduate School of Biomedical Sciences 4500 San Pablo Road, Griffin Building Room 221, Jacksonville, FL 32224, USA. Email: prudencio.mercedes@mayo.edu (M.P.)

Abstract

Numerous reports have suggested that infectious agents could play a role in neurodegenerative diseases, but specific etiological agents have not been convincingly demonstrated. To search for candidate agents in an unbiased fashion, we have developed a bioinformatic pipeline that identifies microbial sequences in mammalian RNA-seq data, including sequences with no significant nucleotide similarity hits in GenBank. Effectiveness of the pipeline was tested using publicly available RNA-seq data and in a reconstruction experiment using synthetic data. We then applied this pipeline to a novel RNA-seq dataset generated from a cohort of 120 samples from amyotrophic lateral sclerosis patients and controls, and identified sequences corresponding to known bacteria and viruses, as well as novel virus-like sequences. The presence of these novel virus-like sequences, which were identified in subsets of both patients and controls, were confirmed by quantitative RT-PCR. We believe this pipeline will be a useful tool for the identification of potential etiological agents in the many RNA-seq datasets currently being generated.

Keywords: ALS; transcriptomics; RNA-seq; microbiome; virome

Introduction

As detailed below, there are numerous reports suggesting that microbes could play a role in neurodegenerative diseases. Microbial sequences are routinely identified in human RNA-seq (RNA-seq) data (Mangul et al. 2018), which is typically acquired to assay gene expression. The origins of these microbial sequences are generally unknown, although in theory disease-relevant microbes could be identified if their sequences are significantly enriched in patients compared with controls. We therefore sought to develop a bioinformatic pipeline that could identify microbial sequences over-represented in RNA-seq data from patients compared with controls. Importantly, our pipeline can recover both known and novel microbial sequences.

Abstract of organisms in neurodegeneration

Infection has been proposed to play a role in multiple neurodegenerative diseases (Patrick et al. 2019), including amyotrophic lateral sclerosis (ALS) (Castanedo-Vazquez et al. 2019). ALS is the most common motor neuron disease in adults, with the majority of individuals dying within 3–5 years of symptom onset. The disease is defined by the degeneration and death of motor neurons in the brain and spinal cord, resulting in progressive weakness and eventually death, typically from respiratory muscle weakness (Mehta et al. 2018). Around 10% of ALS patients have a family history that suggests an autosomal dominant inheritance which is classified as familial ALS (fALS), with the remaining 90% of patients classified as having sporadic ALS (sALS; Masoro and Van Damme 2020). After decades of study, the etiology of sALS remains a mystery, although suspected risk factors for ALS include exposure to heavy metals, pesticides, chemical solvents, cigarette smoke, and unidentified factors related to US military service (Ingre et al. 2015; Talbott et al. 2016; Zhan and Fang 2019; Opie-Martin et al. 2020). Along with these environmental risk factors, there has been a long history, with variable success, in the search for pathogens that might contribute to ALS (Pertschuk et al. 1977; Kohne et al. 1981; Alonso et al. 2017; Xue et al. 2018; Andrade et al. 2019) and other neurodegenerative diseases such as Alzheimer’s disease (AD; Deutch et al. 1982; Taylor et al. 1984; Sochocka et al. 2017), Parkinson’s disease (PD; Irkeç 1982;
Abushouk et al. 2017; Parashar and Udayabanu 2017), and multiple sclerosis (MS; Libbey et al. 2014).

Studies on ALS primarily come from European populations and within ALS primarily four genes [TAR DNA-binding protein 43 (TDP-43), fused in sarcoma/translocated liposarcoma (FUS), superoxide dismutase 1 (SOD1), chromosome 9 open reading frame 72 (C9ORF72)] account for 70% of FALS (Kiernan et al. 2011). Of these four genes, C9ORF72 accounts for up to 30–50% of cases in FALS and 7% of sALS (in all populations; Masrori and Van Damme 2020). In C9ORF72-associated ALS (c9ALS), a hexanucleotide repeat expansion (HRE) occurs that can form RNA with highly stable parallel G-quadruplex structures (G4 RNA). How neurodegeneration occurs from HRE in c9ALS is not well understood, but putative mechanisms include reduction of C9ORF72 expression, production of poly-dipeptides as a result of repeat-associated non-AUG translation of repeat sequences, and the formation of RNA foci that may sequester RNA binding proteins (Reddy et al. 2013; Tang et al. 2020). Identifying disease modifiers is of significant translational interest, as it is currently unknown how patients with c9ALS (sporadic or familial) progress from asymptomatic to symptomatic states. Evidence is mounting that persistent immune activation can play a causative role in disease progression, and some recent treatments focus on reducing the elevated neuroinflammation that occurs in patients with the HRE (Trageser et al. 2019). Indeed, one study showed that a lower abundance of immune-stimulating bacteria contributes to reduced inflammation and protection from premature mortality in a C9orf72 loss-of-function mouse model (Burberry et al. 2020).

Diverse pathogens have been reported in the blood, cerebrospinal fluid (CSF), and central nervous system (CNS) from ALS patients. For example, bacteria that have been detected include Cutibacterium acnes, Corynebacterium sp, Fusobacterium nucleatum, Lausonella clevelandensis, and Streptococcus thermophilus in CSF (Alonso et al. 2019), and mycoplasma in blood (Gil et al. 2014). Fungi, including Candida famata, Candida albicans, Candida parapsilosis, Candida glabrata, and Penicillium notatum, have been detected in CSF, whereas Malassezia globosa, Cryptococcus neoformans (Alonso et al. 2017), and C. albicans have been found in various regions of the CNS (Alonso et al. 2015, 2017; Pisa et al. 2016). The search for viruses that contribute to ALS pathology is much more extensive and includes studies on herpes virus (Pertschuk et al. 1977; Cermelli et al. 2003), enterovirus (Pertschuk et al. 1977; Berger et al. 2000; Giraud et al. 2001; Vandenbergh et al. 2010; Xue et al. 2018), human immunodeficiency virus (HIV; Verma and Berger 2006; Moodley et al. 2019), and human endogenous retrovirus (Douvillé et al. 2011; Li et al. 2015; Arru et al. 2018). Importantly, multiple studies using immunohistochemistry have shown an increased load of various pathogens in ALS samples compared with controls in multiple tissues suggesting these pathogens are present and cannot be simply attributed to contamination (Pertschuk et al. 1977; Alonso et al. 2015, 2017, 2019; Pisa et al. 2016). Ultimately, the presence of ALS dysbiosis is unresolved and remains an active area of investigation with evidence for (Fang et al. 2016; Zhang et al. 2017; Blacher et al. 2019; Sun et al. 2019; Obrenovich et al. 2020) and against it (Brenner et al. 2018).

The biological role that these alternative microbionas play in ALS is also unclear. ALS patients may have a compromised blood brain barrier or blood spinal cord barrier function (Henkel et al. 2009; Garbuzova-Davis and Sanberg 2014). It has been reported that ALS patients also have elevated Gram negative endotoxin/lipopolysaccharide (LPS) in the blood (Zhang et al. 2009). Patients with ALS also display activation of the innate immune system along with changes in blood (Mantovani et al. 2009; Murdock et al. 2017), spinal cord and motor neurons (Sta et al. 2011), but if and how bacteria might influence activation is an active area of research. A “dual hit” hypothesis by Correia et al. (2015) suggests inflammation via LPS may contribute to mislocalization and aggregation of ALS-implicated protein TDP-43.

Numerous studies have looked for biomarkers of ALS (Verber et al. 2019) using metabolomics (Blasco et al. 2010, 2017), neuroinflammation (Mitchell et al. 2009; Guo et al. 2017), DNA methylation (Young et al. 2017; Coppèdè et al. 2018), gene expression (Swindell et al. 2019), microRNA expression (Waller et al. 2017, 2018) and our previous study which analyzed protein levels of poly(GP) in c9ALS (Gendron et al. 2017). The search for pathogens using sequencing data from blood samples in ALS patients has been conducted before (Gagliardi et al. 2018; van Rheenen et al. 2018, Rahman et al. 2019; Zucca et al. 2019), but previous efforts have not looked for novel pathogens. Next-generation sequencing (NGS) technologies have shown broad detection of pathogens in a target-independent unbiased fashion (Moore et al. 2011; Bouquet et al. 2017; Parker and Chen 2017; Westermann et al. 2017), however, designing a microbial detection experiment is nontrivial considering the variety of methods (Poussin et al. 2018) and algorithms (Roumpeka et al. 2017) that can be applied. Our primary goal when designing a new pipeline was to be conservative and unbiased with regards to discovery and quantification of novel pathogens. Furthermore, our intention was not to “reinvent the wheel” for microbiota classification, and instead opt to provide an end-to-end pipeline that leverages data across samples to obtain biologically significant fold changes of microbiota between diseased and healthy subjects.

Although other pipelines have used reads that do not map to the host genome (unmapped reads) for microbial identification and quantification, these pipelines cannot be used for discovery as they rely on existing databases of microbial genomes (Cavadas et al. 2017; Mangul et al. 2018; Simon et al. 2018; Gihawi et al. 2019). One popular pipeline for viral classification that uses nonhost reads includes ViromeScan (Rampelli et al. 2016), which utilizes a database of reference viral sequences to assign reads to taxonomic categories, but is “blind” to viral sequences not closely related to those in the database. Thus, we opted for de-novo assembly of unmapped reads into contigs, similar to the strategy employed by Kraken (Wood and Salzberg 2014) and MetaShot (Fosso et al. 2017). Additionally, we use a hierarchical method to assemble unmapped reads into contigs (single samples, group, and all) to increase the chance of assembling a correct contig from partial sequences that are present in multiple samples, and to remove outlier contigs present in single samples that are unlikely to contribute to the statistical analysis.

Where MetaShot stops at providing reads assigned to taxonomic categories, we map reads back to contigs and provide proper library normalization for statistical quantification. A similar pipeline known as IMSA (Cox et al. 2017) also maps reads back to contigs, but disregards contigs that might be identified by translated amino acid sequence similarity using BLASTX (a set we call the “dark biome”) as well as subsequent contigs with no BLASTN or BLASTX hit (a set we call the “double dark biome”). We validated our pipeline by using datasets (synthetic and real) with known bacterial or viral infections. We also examined the differences in microbial identification between polyA and total RNA recovery in multiple tissues, and investigated the effects of globin depletion of blood samples. We then used our pipeline on a novel ALS blood dataset (termed “Our Study”) as well as on five other published ALS datasets from blood or spinal cord samples, analyzed each dataset individually, and analyzed across
datasets for changes in microbiota. Although we did not identify any microbes enriched in the blood of ALS patients, we did identify and validate a novel virus-like sequence, demonstrating the potential of the bioinformatic pipeline we have established.

**Materials and methods**

**Blood collection and RNA extraction**

A total of 120 RNA whole blood samples constitute Our Study, which included 30 healthy controls (from general population that do not have blood relatives suffering from ALS, CTL), 30 symptomatic C9ORF72 mutant carriers (C9A), 30 symptomatic C9ORF72 ALS cases (C9S), and 30 symptomatic C9ORF72-negative ALS cases (SYM). PAXgene blood RNA tubes were collected at Mayo Clinic Jacksonville and at University of Miami. All 120 RNA samples selected for RNA-seq were received and processed at Mayo Clinic Jacksonville using PAXgene blood RNA kit following manufacturer’s recommendations (Qiagen). Blood RNA was of high quality, assessed in an Agilent Bioanalyzer (Agilent), with RNA integrity values ranging from 7.4 to 9.8, with a median value of 8.7. RNA samples were then sent to The Jackson Laboratory for globin depletion, library preparation and sequencing of total blood RNA.

**Globin depletion**

Due to the abundance of large hemoglobin RNA transcripts present in the blood, a globin depletion step, using the Ambion GLOBINclear kit (AM1980), was performed before sequencing of the blood RNA samples in order maximize coverage on nonglobin genes. In brief, one microgram of total RNA was used as starting material, and specific biotinylated oligos were used to capture globin mRNA transcripts. The capture oligos were hybridized with total RNA samples at 50°C for 30 min. Streptavidin magnetic beads were then used to bind to the biotinylated capture oligos hybridized to globin mRNA by incubating at 50°C for 30 min. The magnetic streptavidin beads-biotin complex were then captured to the side of the tubes by a magnet, and the resulting supernatant is free of globin mRNA. The globin depleted (GD) RNA was further purified by RNA binding beads and finally eluted in elution buffer. The resulting RNA free of >95% globin mRNA transcripts was then processed for NGS. Of note, to assess the efficiency of the globin RNA depletion, 10% of the samples processed were selected randomly and amplified using a Target-Amp Nano labeling kit (Epicentre). Samples were normalized to 100 ng input and reverse transcribed. First strand cDNA was generated by incubating at 50°C for 30 min with first strand premix and Superscript III. This was followed by second strand cDNA synthesis through DNA polymerase by incubating at 65°C for 10 min and at 80°C for 3 min. In vitro transcription was then performed at 42°C for 4 h followed by purification using RNeasy mini kit (Qiagen).

Due to the large number of samples, the globin depletion step was performed in two batches. We provided guidelines on how samples would be divided among the batches and also for how samples would be grouped in the sequencing runs in order to minimize technical variability. The Jackson Laboratory personnel were blinded to the identity of the samples.

RNA-seq of total blood RNA (globin and ribosomal RNA depleted) was performed in an Illumina HiSeq4000 with >70 million read pairs per sample (100 bp read lengths). Raw reads were then sent back to us for bioinformatics analyses.

**Quantitative RT-PCR for blood RNA samples**

A total of 500 ng of total blood RNA was used for reverse transcription polymerase chain reaction (RT-PCR), using the high-capacity complementary DNA Transcription Kit with random primers (Applied Biosystems). Quantitative real-time PCR (qRT-PCR) was performed using SYBR GreenER qPCR SuperMix (Invitrogen). Samples were run in triplicate, and qRT-PCRs were run on a QuantStudio 7 Flex Real-Time system (Applied Biosystems).

List of primers and their sequences in this study:

- Primers targeting the novel RNA-dependent RNA polymerase (RDRP) contig from our study:
  - RDRP forward 5'-GCTGTCAAATCGGTTCACAC-3';
  - RDRP reverse 5’-CTGCCCTCCGTATCCTTGGAG-3’.
- Primers targeting highly expressed control regions:
  - GAPDH forward 5’-GTTTGACAGTGCCGATC-3’;
  - GAPDH reverse 5’-GGAATTTCGATGGTGGA-3’.

**Transcriptomics**

See pipeline description in results for an overview of the pipeline; see bioinformatics Supplementary File S1 for a more detailed description of the analysis pipeline, versions, and statistical quantification. For downloading the pipeline and detailed instruction for running the pipeline please read the README at https://github.com/Senorelegans/MysteryMiner. We have also deposited a frozen and cite-able version of the software with doi:10.5281/zenodo.4598807 and available at https://zenodo.org/record/4598807#.YEphh5NKjKp. All data in this study were processed identically using the pipeline.

**Statistical analysis**

To assess statistical differences between conditions, a two tailed Student’s t-test was calculated using normalized coverage (NC) or counts or binned normalized coverage (BNC) for species/gens, etc. The number of consigs or genus/species is used to obtain an False discovery rate (FDR) corrected (using the Benjamini/Hochberg method) adjusted P-value (q-value) via statsmodels in Python. Cutoff for statistical significance is less than an q-value of 0.05 unless otherwise stated.

**Results**

**Pipeline description**

Our novel pipeline, Mystery Miner, is written as a Nextflow pipeline. Below is a short overview of the Mystery Miner pipeline (Figure 1). A more in-depth explanation, list of software and versions used, and typical parameters of each step are described in the bioinformatics supplement, and all of the code used in this article can be found at https://github.com/Senorelegans/MysteryMiner.

Raw reads were first checked for quality using FastQC then trimmed to remove both adaptor contamination and low quality basecalls using Trimmomatic. Trimmed reads were then mapped to the host genome using STAR for a fast first-pass followed by a second pass with bowtie2 for sensitivity. Unmapped reads were retained for contig assembly. Filtering out host reads made downstream assembly faster and required less memory. We assembled contigs from unmapped reads with the SPAdes assembler (with “-rma” setting). This assembler was chosen for its recent use in studies of microbial diversity (Almeida et al. 2019).
and proven robustness to biological and technical variation (Papudeşti et al. 2017). The species each contig belongs to was identified with BLASTN using default settings, and the top hit for each contig was retained (a set we call "regular biome"). Contigs with no BLASTN hits were then filtered to remove highly repetitive regions (DUST). Next, contigs were retained if they had a >60% pairwise alignment (LAST) between contigs assembled from a single sample, group/condition, or all samples (for example, contigs from groups that match singles are retained, we then use this new set to match with contigs from the all assembly).

We then identified contigs that lacked detectable nucleotide similarity to any GenBank entry but showed similarity at the amino acid level using BLASTX ("dark biome"). Furthermore, contigs with no BLASTN or BLASTX hits were labeled as "double dark biome" (also filtered by DUST and LAST). Every contig in the "regular biome" and "dark biome" were then queried against the Joint Genome Institute Server for additional taxonomic information. As Mystery Miner is an agnostic tool, it cannot distinguish between true tissue or cell-associated microbes and experimentally introduced contamination.

For quantification, we mapped the nonhost reads using Bowtie2 to the contigs obtained from SPAdes. Next, we mapped reads to contigs using samtools mpileup (default mapq score) to calculate the amount of reads over each base pair in a contig. We then calculated coverage on the contigs by summing all of the reads for each base pair in a contig and dividing by the length of the contig. We then calculated NC by library size using the number of mapped reads to the host genome. This gave us NC for a contig or BNC for multiple contigs within a species/genus, etc. To assess statistical differences between conditions, a Student’s t-test was calculated through NC or BNC, using the number of mapped reads to contigs using samtools mpileup (default mapq score) to calculate the amount of reads over each base pair in a contig. We then calculated coverage on the contigs by summing all of the reads for each base pair in a contig and dividing by the length of the contig. We then calculated NC by library size using the number of mapped reads to the host genome. This gave us NC for a contig or BNC for multiple contigs within a species/genus, etc. To assess statistical differences between conditions, a Student’s t-test was calculated through NC or BNC, using the number of contigs or genus/species to obtain an FDR corrected adjusted P-value (q-value) using statsmodels in Python.

**Validating Mystery Miner on datasets with known bacterial or viral infection**

To confirm that Mystery Miner is able to recover and quantify known bacterial infections from sequencing data, we utilized an in vitro model of *Chlamydia trachomatis* infection from (Humphrys et al. 2013). In this study, epithelial cell monolayers were infected with *C. trachomatis*; and polyA RNA (six samples) and total RNA (six samples) were sequenced 1 and 24 h postinfection (hpi). Using the Mystery Miner pipeline, out of $5.32 \times 10^8$ reads from all of the samples, $6.04 \times 10^7$ reads remained unmapped (~11.34%) after trimming and mapping to the host genome (Supplementary File S2). From these nonhost reads, 3257 contigs were assembled and 1199 of these contigs were identified as regular biome (Supplementary File S3). An additional 27 contigs had no BLASTN hit. Of these, we identified two dark biome (BLASTX identified) and no double dark biome (no BLASTX or BLASTN hit) contigs (Supplementary Files S4 and S5).

Using Mystery Miner we successfully identified, and found significantly elevated levels, of *C. trachomatis* (BNC by species) in 24 hpi samples compared with 1 hpi samples in both polyA ($q = 0.004$) and total RNA ($q = 0.0005$). In addition to *C. trachomatis*, we identified six additional bacterial species and one viral species (*Alphapapillomavirus 7*) in the samples (Figure 2A), including significantly elevated levels of *Mycoplasma hyorhinis* contigs in total RNA samples. No significant differences were observed in the dark or double dark contigs (Supplementary File S6).

To confirm that the pipeline can detect known viral infections, we ran Mystery Miner on a total RNA dataset from an in vitro model of severe acute respiratory syndrome coronavirus (SARS-CoV-1 or -2 infection (Emanuel et al. 2020)). In this study, human epithelial Calu3 cells were infected with SARS-CoV-1 or SARS-CoV-2 (4, 12, or 24 h), mock (4 or 24 h), or untreated (4 h).

Out of the 2.81 $\times 10^8$ reads obtained from all of the samples, $8.23 \times 10^7$ reads remained unmapped (~29%) after trimming and mapping to the host genome (Supplementary File S2). From these nonhost reads, 42,816 contigs were assembled, of which 1346 regular biome, 27 dark biome, and 7 double dark biome contigs passed the filtering steps (Supplementary Files S2–S5).

Mystery Miner successfully identified both SARS-CoV-2 and SARS-CoV-1 isolates and found significantly elevated levels of each virus compared with controls (Figure 2B). Hereafter, we refer to SARS-CoV-1 or SARS-CoV-2-infected cells as COV1 or COV2 to......
avoid confusion with recovered names of contigs. Consistent with the viruses being similar, we identified both SARS-CoV-2 and SARS-CoV-1 in both the COV1-24hr and COV2-24hr samples when compared with mock-24hr. However, when we compared COV2-24hr to COV1-24hr, we were able to distinguish SARS-CoV-1 isolates from SARS-CoV-2 in the appropriate samples (i.e., SARS-CoV-2 was significantly elevated in COV2). Similar results were seen in the 12h samples but the 4h samples did not have sufficient viral reads to detect either SARS-CoV virus (Supplementary File S7). To simulate a novel virus, we ran Mystery Miner on versions of the BLASTN and BLASTX databases obtained before SARS-CoV-2 was discovered and were able to properly identify SARS-CoV-2 as a bat-related CoV (Boni et al. 2020; Supplementary Figure S1 and File S7).

Collectively, these data show that Mystery Miner is able to identify potential bacterial and viral infections, properly identify infected samples using quantification, and detect significant differences between infected samples and controls for bacteria, viruses, and isolates of a virus.

Validating Mystery Miner on a synthetic minibiome

We next looked at the detection and quantification limits of Mystery Miner using generated read data to create a synthetic minibiome. We used Polyester (Frazee et al. 2015) to generate paired end read data (100 bp read size) at various coverage levels and various fold change differences between two groups (groups A and B) with 10 samples each (20 samples total, read S1 for methods). Our synthetic minibiome consists of 10 human sequences and 10 sequences from nonhuman organisms (4 pathogenic and 6 commensal). The first four organisms in the synthetic minibiome are SARS-CoV-1, SARS-CoV-2, C. trachomatis, and Chlamydia pneumoniae. The next six (Mageebacillus indolicus, Prevotella melaninogenica, Filifactor alocis, Mobiluncus curtisii, Rothia dentocariosa, and Aeromicrobium marinus) are commensals that are part of the representative bacteria list from the Human microbiome project (Ribeiro et al. 2012).

For the human sequences, we first generated a pool of human reads using the first 10 kb of 10 scaffolds from chromosome 22 (default value for human read generation in Polyester) at 1000× coverage with no fold change differences between groups. For nonhuman organisms, we took the first 10 kb of the nucleotide sequence for the organism and generated reads at coverage levels of 100×, 100×, 1×, 0.1×, and 0.01×. Last, we combined the 1000× coverage human reads separately with each level of coverage for nonhuman organisms and ran Mystery Miner (six pipeline runs in total).

We found sequences below 1× coverage did not assemble, suggesting that this is our limit of detection (all further data omits 0.1× and 0.01× coverage). For the SARS strains, we successfully identified both strains at 1000× coverage but found that with lower coverage levels, SARS-CoV-1 was identified as a SARS-related CoV. This ambiguity is likely due to the 73% nucleotide sequence identity (aligned with CLUSTAL OMEGA; Ninfali 2003) between the first 10 kb of SARS-CoV-1 and SARS-CoV-2. For the selected Chlamydia species (59% sequence identity of the first 10 kb) and the rest of the commensal bacteria, we were able to successfully assemble and correctly identify each species at every level of coverage.

Along with identification, we looked at Mystery Miners ability to quantify fold change differences between groups (A and B) using the synthetic minibiome. For the four pathogenic organisms, we selected one sequence from each kingdom to have a twofold difference (SARS-CoV-2, C. trachomatis). For the six commensals, we chose the first three species to have fold change differences of 1.8, 1.5, and 1.3 (M. indolicus, P. melaninogenica, and F. alocis). For SARS, we found that at 1× coverage, the twofold difference of SARS-CoV-2 was correctly called significant (p = 5.14 × 10⁻¹⁰), but the ambiguously identified SARS-related CoV contig was not called significant (p = 0.489). At 1000× coverage, we found that the correctly identified SARS-CoV-1 contig was falsely called significant (p = 0.0028), this is likely due to ambiguous read mapping from the closely related SARS-CoV-2 sequence, as mentioned above. We found similar results for each coverage level (from 1× to 1000×) for the rest of the organisms and will subsequently use...
values from 1× coverage as that is the lowest level of detection. For Chlamydia, we found Mystery Miner successfully called C. trachomatis significant (q = 3.57 e⁻¹⁰) and C. pneumoniae not significant (q = 0.709). For the commensals with FC differences, we successfully called each one significant [M. indolicus (q = 6.92 e⁻⁷), P. melaninogenica (q = 4.91 e⁻⁸), F. alocis (q = 0.017); Figure 3 and Supplementary File S7]. Using synthetic data, we conclude that Mystery Miner is able to identify organisms down to the species level and correctly call significant fold changes at low levels of coverage but has difficulty from ambiguity when reads come from highly similar sequences (>72%).

Effects of library pulldown or globin depletion in RNA-seq datasets
In order to compare effects of library enrichment or depletion, we compared recovered pathogens in a dataset that has polyA enrichment or rRNA depleted total RNA from blood or colonic tissue (Zhao et al. 2018). When we compared polyA RNA versus total RNA and looked at BNC by superkingdom of bacteria we found significantly more reads map to bacteria for total RNA than polyA RNA (q = 0.0349), in blood but not in colon (q = 0.11709; Supplementary Figure S2 and File S8). We found similar amounts of significant BNC by species for polyA RNA versus total RNA in blood (29) and in colon (26). We then looked at significant BNC by genus and found double the amount in blood (14 compared with colon (7), with only one significant genus (Actinomyces) found in both comparisons. We did not find any significant differences in coverage when we looked at the species, genus or superkingdom level for viruses (Supplementary File S8). We conclude that library enrichment with total RNA compared with polyA RNA increases bacterial recovery and diversity in blood.

We next looked at a RNA-seq dataset from whole blood with GD versus nonglobin depleted (NGD) total RNA (Shin et al. 2014). With BNC by superkingdom, we found significantly increased levels in GD versus not-depleted samples for both bacteria (q = 0.004; Supplementary Figure S3) and viruses (q = 0.030; Supplementary Figure S4). We also found significant differences in BNC by species (Supplementary Figure S5) or genus

Figure 3: Heatmap of coverage of synthetic mini-bio (1x coverage).
Heatmap of coverage for synthetic mini-bio at 1× coverage. Fold change (FC) in the row name refers to group A (red) over group B (black). The first four rows are pathogenic organisms, the next six rows are commensals identified from the human microbiome project.

Figure 4: Log number of bacterial species versus Log reads for Assembly in Our Study. Scatterplot where each dot is a sample from a dataset with log number of bacterial contigs assembled on the Y-axis and Log reads used in SPAdes on the X-axis. Samples show a modest correlation (Pearson’s r = 0.37) between library size and bacterial species recovered. Data fit with a regression (black line) and 95% CI (gray area).

Analysis of our study
We used Mystery Miner on our novel RNA-seq dataset of GD and rRNA depleted total blood RNA from 120 individuals. These samples were from four subject groups including healthy control participants (CTL), ALS symptomatic C9ORF72 negative patients (SYM), C9ORF72 positive ALS symptomatic patients (C9S), and C9ORF72 positive asymptomatic individuals (CSA).

The entire dataset contains a combined 8.64 × 10⁹ reads. Approximately 2.7% (2.34 × 10⁸) of the reads did not map to the human genome. From these nonhost reads 2,976,988 contigs were assembled and 17,047 BLASTN contigs (regular biome) were identified. A total of 25,815 contigs had no BLASTN hit and after filtering we identified 2,980 dark biome (BLASTX identified) and 859 double dark biome (no BLASTX or BLASTN hit) contigs (Supplementary Files S2–5).

In general, we found a modest positive correlation between library size and number of bacterial contigs assembled, species detected (Figure 4), and genera detected for each sample as well as a homogenous mixture of samples with respect to disease status. No specific taxonomy or contig sequence correlated with participant class within the dataset. By pooling bacterial read counts across all of the samples, we found alpha proteo-bacteria, Actinobacteria, Firmicutes, and Bacteroidetes as the most highly represented taxonomies, consistent with other blood biome studies (Castillo et al. 2019, Supplementary Figure S7). Most of the bacterial genera (~65%) assigned to the dark biome contigs were also found in the regular biome; however, this was not the case in the viral sets, as only 5% (4/78) of dark viral contigs were observed in the regular biome (Supplementary File S10).
suggested that our pipeline might be identifying novel viral sequences.

Within the dark biome contigs, we noted numerous contigs with a region of protein sequence similarity to RDRP from multiple RNA viruses, including the velvet tobacco mottle virus (first row in heatmap of Figure 5, complete metadata shown in Supplementary Figure S8). Our attention was drawn to the largest (~5 kb) dark biome contig hereafter labeled as “RDRP contig.” This large contig showed no nucleotide sequence similarity to any sequence in GENBANK, and no protein sequence similarity except for a long open reading frame with significant similarity to viral RDRPs (BLASTX \( P = 1 \times 10^{-26} \)). A phylogeny based solely on viral RDRP protein sequences places the RDRP contig closest to single-stranded (+) viruses of the Barnavirus, Sobemovirus, and Polerovirus genera (Supplementary Figure S9 and File S1 for methods). However, given the absence of detectable similarity in this contig to other (non-RDRP) viral proteins of these genera, the relationship of the contig sequence to other virus groups is unclear, which supports the view that this contig represents a novel viral sequence.

To confirm the presence of the RDRP contig in the original samples, we designed primers to the RDRP contig and performed RT-PCR on seven samples, four of which had high coverage (predicted present) and three with zero coverage (predicted absent).

Figure 5 Heatmap of dark biome contigs binned by species in Our Study. Heatmap of NC of dark biome contigs binned by species. The highest coverage belongs to contigs that show high similarity to velvet tobacco mottle virus. Zero coverage is dark blue and goes to yellow with increasing values. These samples were from four subject groups including healthy controls \([\text{CTL}\text{ green}]\), C9ORF72 negative ALS symptomatic \([\text{SYM}\text{ purple}]\), C9ORF72 positive ALS symptomatic \([\text{C9S}\text{ blue}]\), and C9ORF72 positive asymptomatic \([\text{C9A}\text{ red}]\) patients. Sex indicated as light blue (male) and pink (female). Top 100 species sorted by BNC shown for brevity.
We found typical levels for detection of a virus in the samples with high coverage and detected no signal above background in samples with zero coverage (Table 1). We conclude that Mystery Miner can recover true novel sequences that could represent previously unknown pathogens.

### Analysis of published ALS datasets

We next sought to explore whether similar results would be obtained from other ALS datasets. To this end, we examined five other publicly available ALS datasets, consisting of two that used total RNA from blood (Linsley et al. 2014; Gagliardi et al. 2018) and three datasets from spinal cord (Brohawn et al. 2016, 2019; Bennett et al. 2019). We have provided a summary table of datasets for all studies used in this article (Table 2). As we observed in Our Study, we first noted that increased library size correlated with an increased number of bacterial contigs assembled, species detected, and genera detected (Figure 6 and Supplementary Figure S10–12 show all datasets used in this study).

We then looked at the total overlap of genus or species to determine if there are similarities in recovered microbial or viral sequences between datasets. For genus in the regular bacteriome, our dataset had the highest number of unique genus (185), followed by Ladd et al. (2017; 117), and Gagliardi et al. (2018; 38). The highest number of overlapping bacterial genus was between our dataset and Ladd et al. (2017; 133) followed by the intersection between our dataset (Ladd et al. 2017; Gagliardi et al. 2018; 61) and there was a modest overlap (24) for 9/10 datasets (Figure 7). We observed roughly the same trend in the regular bacterial biome at the species level and in the dark bacterial biome (Supplementary Figures S13 and S14 and File S11). In contrast, the regular virome of each dataset was relatively unique with very low amounts of overlap (<3) between datasets (species and genus shows a similar pattern). Interestingly, the highest overlap for species in the dark virome was between our dataset and (Ladd et al. 2017; 13), one of which is similar to RDRP viruses, although the contigs in Ladd’s data were not similar to the velvet tobacco mottle virus in our dataset (Supplementary Figures S15 and S16). We then looked at the total overlap of genus or species to determine if there are similarities in recovered microbial or viral sequences between datasets. For genus in the regular bacteriome, our dataset had the highest number of unique genus (185), followed by Ladd et al. (2017; 117), and Gagliardi et al. (2018; 38). The highest number of overlapping bacterial genus was between our dataset and Ladd et al. (2017; 133) followed by the intersection between our dataset (Ladd et al. 2017; Gagliardi et al. 2018; 61) and there was a modest overlap (24) for 9/10 datasets (Figure 7). We observed roughly the same trend in the regular bacterial biome at the species level and in the dark bacterial biome (Supplementary Figures S13 and S14 and File S11). In contrast, the regular virome of each dataset was relatively unique with very low amounts of overlap (<3) between datasets (species and genus shows a similar pattern). Interestingly, the highest overlap for species in the dark virome was between our dataset and (Ladd et al. 2017; 13), one of which is similar to RDRP viruses, although the contigs in Ladd’s data were not similar to the velvet tobacco mottle virus in our dataset (Supplementary Figures S15 and S16 and File S12).

In addition to comparing datasets using taxonomy, we also compared contigs between datasets for nucleotide similarity (>70%) using LAST (Supplementary File S1 for methods). We

### Table 1 RT-PCR and NC results for RDRP contig

| Condition | Sample | GAPDH RT-PCR Ct value | RDRP RT-PCR Ct value | RDRP RNA-seq NC |
|-----------|--------|-----------------------|----------------------|-----------------|
| SYM       | LP00274| 20.562019              | 36.401               | 1.56            |
| C9S       | LP00041| 20.783213              | 36.346               | 3.39            |
| C9S       | LP00192| 20.896912              | 35.636               | 0.67            |
| C9A       | LP001180| 19.982108             | 34.832               | 1.11            |
| C9S       | LP001183| 20.176418             | Undetermined         | 0               |
| C9S       | LP001197| 20.125161             | Undetermined         | 0               |
| C9A       | LP001157| 20.062433             | Undetermined         | 0               |

qRT-PCR and NC results from the S180 bp RDRP contig. For the RDRP contig positive samples (top 4) with high NC and detectable Ct values and negative samples (bottom 3) with no NC and undetectable Ct values. GAPDH was used as a positive control for qRT-PCR and shows comparable levels for all samples. These samples were from three conditions: C9ORF72 negative ALS symptomatic patients (SYM), C9ORF72 positive ALS symptomatic patients (C9S), and C9ORF72 positive asymptomatic individuals (C9A).

### Table 2 Study design for datasets used in this article

| Name               | Groups                                | No. of Samples | Tissue                                | Pulldown                                |
|--------------------|---------------------------------------|----------------|---------------------------------------|-----------------------------------------|
| Humphrys et al. (2013) | 1 or 2 hpi with C. trachomatis       | 12             | Cultured epithelial cell monolayers   | PolyA RNA                               |
| Zhao et al. (2018)   | Polya or total RNA from blood or colon | 16             | Whole Blood                           | Polya RNA                               |
| Shin et al. (2014)   | GD                                    | 24             | Colon                                 | Total RNA                               |
| Emanuel et al. (2020) | SARS-CoV-1 or -2 infection Controls | 18             | Calu3 cells                           | Total RNA                               |
| Our Study           | C9ORF72 negative ALS                  | 120            | Whole blood                           | Total RNA hemoglobin and rRNA depleted  |
|                    | C9ORF72 positive and symptomatic ALS  |                 |                                        |                                         |
|                    | C9ORF72 positive asymptomatic         |                 |                                        |                                         |
|                    | participants                           |                 |                                        |                                         |
|                    | Controls                              |                 |                                        |                                         |
|                    | ALS                                   | 134            | Whole blood                           | Total RNA                               |
|                    | Type 1 diabetes                        |                 |                                        |                                         |
|                    | Sepsis                                |                 |                                        |                                         |
|                    | MS patients before and 24 h           |                 |                                        |                                         |
|                    | after the first treatment with IFN-bta|                 |                                        |                                         |
|                    | Controls                              | 20             | Peripheral blood mononuclear cells    | Total RNA                               |
|                    | sALS                                  |                 |                                        |                                         |
|                    | ALS with mutations in FUS, SOD1, and TARDBP Controls | 53             | Cervical spinal cord                   | Total RNA                               |
| Bennet et al. (2016) | ALS                                   | 15             | Cervical spinal cord                   | Total RNA                               |
| Ladd et al. (2017)   | ALS                                   | 10             | LCM to isolate cervical spinal        | Total RNA                               |
|                      | cord motor neurons                    |                 | cord                                  |                                         |
| Brohawn et al. (2019) | ALS, AD, and PD                       | 53             | Cervical spinal cord                   | Total RNA                               |

Overview of the datasets used in this article. The first three studies are only used to validate our pipeline. The six subsequent studies are ALS related from both blood and spinal cord.
found that in general, datasets in the regular biome with the largest amount of contigs have the most overlap. Unsurprisingly, in the dark biome we observed less overlap by nucleotide similarity and that our RDRP contig does not share nucleotide similarity with contigs from any dataset. In addition, we also compared the nucleotide similarity of double dark biome contigs and found there is not a large percentage of similar contigs between datasets (Supplementary File S13).

**Comparison of taxonomy by condition within ALS datasets**

Finally, we looked for differences in ALS versus control samples for each dataset. In the Gagliardidataset, when we compared ALS patients with the FUS mutation to controls, we found three significant differences in BNC by species in the regular bacteriome (Neisseria sp., Pseudomonas sp., and Sphingomonas sp.) and one significant difference in BNC by genus in the dark bacteriome (Photobacterium). In ALS patients with mutations in SOD1 compared with controls, we found two species significantly different in the regular bacteriome (Hydrogenophaga crassostreae and Sphingomonas hengshuiensis). We did not find anything significant in sALS, or in ALS patients with TARDBP mutations with regards to genera/species count (regular or dark biome or viruses) for Gagliardi. We found no significant statistical differences between ALS and control samples for genus/species count of viruses/
bacteria in the regular/dark biome for any of the remaining ALS datasets.

Meta-analysis between datasets

Since our dataset and many others had few to no significant comparisons for ALS versus control groups within each dataset, a meta-analysis between datasets using this criteria would be difficult. As a second pass analysis we created a less stringent filtering method in order to compare the presence of microbes for each group between datasets (ALS vs. ALS; or controls vs. controls; Figure 8). We assigned a contig to a condition if ≥2 samples from that condition contain at least 90% of the summed NC (from all samples) to the contig. This filtering greatly reduced the number of comparable genus/species for each dataset and, for example, reduced the genus of the regular bacteriome in our dataset from 305 for all samples to 33 (SYM: 8, C9S: 6, C9A: 2, and CTL: 17; Supplementary File S14).

When we looked at ALS or control contigs in the regular bacteriome, the highest number of unique genus or species was from Ladd et al. (2017), and in general there was a small amount of overlap between datasets (≤1 for ALS or ≤8 for controls; Figure 8). When we looked at genus in the dark bacteriome we saw no overlap for ALS contigs and low overlap (≤1) between control conditions (species was similar; Supplementary Figures S17 and Supplementary 18 and File S14). In the regular virome there was no overlap between datasets and only our study (one contig from ALS) and Ladd et al. (2017; three from ALS and five from controls) had contigs that passed the filter (similar values for species). When we looked in the dark virome by genus there was no overlap between datasets and our dataset had only one genus (Sobemovirus from controls) with the rest coming from Ladd et al. (2017; 18 from controls and 5 from ALS; Supplementary File S15).

In conclusion, despite our conservative and loose approaches, we did not find any convincing evidence in ALS samples that the presence (or lack of presence) of an organism (or multiple organisms) was different compared with control samples.

Discussion

We have created Mystery Miner to search for and quantify known and unknown microbes in RNA-seq datasets as a tool for researchers to study dysbiosis and identify infectious agents. We validated the pipeline by recovering and quantifying Chlamydia and SARS-CoV reads from RNA-seq datasets from intentionally infected cells. Interestingly, we also identified Mycoplasma reads in the Chlamydia dataset, suggesting that Mystery Miner may also be able to identify unsuspected bacterial infections or contamination. Next, we created a synthetic minibiome of two different Chlamydia species and SARS strains, along with six representative bacteria from the human microbiome to investigate the sensitivity of Mystery Miner with regards to species and strain detection and quantification of small fold changes at low coverage. We find that the pipeline is able to recover and quantify significant fold changes for the bacterial species but has difficulty distinguishing reads that come from highly related sequences. We also use published data to investigate the difference of polyA versus total RNA recovery of bacterial species in multiple tissues. Perhaps surprisingly, we did not see a consistent difference in the recovery of bacterial reads between the two types of RNA-seq libraries, considering that bacterial transcripts are not expected to be polyadenylated. However, it is well-recognized that polyA selection is imperfect, and libraries constructed from polyA-selected RNA routinely contain transcripts thought not to be polyadenylated (e.g., rRNA). We also found increased recovery of bacterial species with globin RNA depletion in blood. This could be the result of an effective increase in read depth for bacteria when not sequencing globin, or an increase in contamination from the globin depletion step. We stress that our bioinformatic approach alone cannot distinguish between contamination and the true existence of microbial sequences in human tissue.

We then used Mystery Miner on a novel ALS blood dataset (Our Study) consisting of 8.64 × 10^9 reads. This dataset was generated from whole blood total RNA that was depleted for both...
ribosomal and globin transcripts. It encompasses samples from controls, participants with a C9ORF72 hexanucleotide expansion (symptomatic and presymptomatic), and C9ORF72 negative ALS patients. We found no statistical difference in microbial sequence read coverage between controls and any class of ALS patients, examining either individual contigs or using various taxonomical binning approaches. We also did not detect any batch effects or obvious age or sex biases in the recovery of microbial reads (Supplementary Figure S8). Overall, we found no evidence of blood microbial sequences contributing to either C9ORF72 negative ALS or symptomatic patients harboring the C9ORF72 hexanucleotide expansion. However, ALS is a CNS disease, so our findings in these blood samples do not necessarily preclude a role for microbes in this disease.

A unique aspect of Mystery Miner is that it tracks nonhuman reads that do not have significant BLASTN hits in GenBank. We were intrigued by the identification of a large contig (>5 kb) in the dark biome of our ALS dataset that showed protein sequence similarity to RDRPS, the essential replicase of RNA viruses. To validate that this virus-like sequence was not an artifact of contig assembly or a contaminant introduced during library construction or sequencing, we used RT-PCR of the original patient samples to demonstrate that this sequence was present in positive samples identified through the RNA-seq analysis and not detectable in negative samples. We cannot extrapolate from this specific example to determine what fraction of the “dark” and “double dark” sequences represent true novel microbial sequences present in human blood, but we note that analysis of human cell-free blood DNA has reported the identification of thousands of novel bacterial sequences (Kowarsky et al. 2017). We suggest that Mystery Miner is a generally useful tool for the identification of novel microbial sequences in RNA-seq data.

To extend our analysis we processed publicly available blood and spinal cord ALS datasets through our pipeline. As observed in our dataset, library size generally correlated with number of bacterial contigs assembled and number of bacterial genera/species recovered. When the microbial sequences we found in our dataset were compared with the other datasets we found similar genera/species and, not surprisingly, larger datasets generally had greater overlap. One dataset (Ladd et al. 2017) yielded comparable recovery of bacteria and viruses for the regular biome but a far greater recovery bacteria and viruses in the dark biome compared with all the other datasets. This study used laser capture microdissection (LCM) to isolate cervical spinal cord motor neurons and had comparable read amounts per sample to other studies and was conducted in the same laboratory as two other studies (Brohawn et al. 2016). We are unsure why this dataset yielded a much larger dark biome compared with the other datasets. Potentially these differences are a byproduct of using LCM to acquire samples.

We then analyzed several publicly available ALS datasets for statistically significant differences between recovered microbial sequences in ALS and control samples. Only one dataset (Cagliardi et al. 2018) had any significant microbial sequence differences between control and ALS samples, specifically ALS patients with FUS or SOD1 mutations. However, the sample number in this sub-study was small (n = 2–3), and in the case of the SOD1 patients the excess microbial reads were in the control samples. In the absence of additional information (e.g., batch assignments for the samples) it is difficult to conclude that these sequence/sample correlations are meaningful. Finally, we compared identified microbial sequences in the control and ALS samples across the datasets and did not identify any genera/species that were preferentially recovered in either sample type.

Using our bioinformatic analysis pipeline Mystery Miner, we have not identified an association between ALS pathology and sequences corresponding to known or unknown microbial species. However, there are intrinsic limitations in using “repurposed” RNA-seq data to assay tissue-associated microbial sequences, including the relatively small number of nonhuman reads (<1% of total) upon which the analysis is based. This limited sequence signal could preclude identification of rarer microbes. Perhaps more problematic is the possibility that contaminating sequences obscure true tissue-associated microbial sequences. Any candidate microbes identified using Mystery Miner that correlate with human phenotypes will necessarily require independent validation. Despite these limitations, we believe Mystery Miner will be a useful tool for future researchers investigating known and unknown microbes that could contribute to disease, as our analyses have shown it to be sensitive to bacterial/viral agents in sequencing data.

Data availability

Raw sequencing data for Our Study dataset is available in the NCBI Sequence Read Archive under the accession number PRJNA715316.

All other datasets are publicly available, and all of the code used in this article is available at https://github.com/Senorelegans/MysteryMiner. Supplementary material available at figshare: https://doi.org/10.25387/g3.13315181.

Acknowledgments

We thank the Jackson Laboratories for globin depletion and RNA-seq to generate Our Study dataset.

Funding

This work was supported by the NIH (NS063964 to C.L.); the ALS Association (ALSA, to L.P.; WA1096 and 16-IIF-253 to M.P.; and no. 2015 to M.B.); NINDS (R35NS097273 and P01NS084974 to L.P.); the Mayo Clinic Foundation (to L.P.); Neuroscience Focused Research Team Mayo Clinic grant (to M.P.); the Association of Frontotemporal Dementia (AFTD, to L.P.); the Alzheimer’s Association-AD Strategic Fund (to L.P.); the Muscular Dystrophy Association (MDA no. 172123 to M.B.); the ALS Recovery Fund (to M.B.); Kimmelman Estate (to M.B.); and the Department of Defense (Chem-Bio Diagnostics program Grant HDTRA-1-18-1-0032 to R.D.D.).

Conflicts of interest

We declare there are no conflicts of interest.

Literature Cited

Abushouk AI, El-Husseny MWA, Magdy M, Ismail A, Attia A, et al. 2017. Evidence for association between hepatitis C virus and Parkinson’s disease. Neurol Sci. 38:1913–1920. doi:10.1007/s10072-017-3077-4

Almeida A, Mitchell AL, Boland M, Forster SC, Gloor GB, et al. 2019. A new genomic blueprint of the human gut microbiota. Nature. 568:499–504. doi:10.1038/s41586-019-0965-1
Alonso R, Pisa D, Carrasco L. 2019. Searching for bacteria in neural tissue from amyotrophic lateral sclerosis. Front Neurosci. 13:171. doi:10.3389/fnins.2019.00171

Alonso R, Pisa D, Fernández-Fernández AM, Rábano A, Carrasco L. 2017. Fungal infection in neural tissue of patients with amyotrophic lateral sclerosis. Neurobiol Dis. 108:249–260. doi:10.1016/j.nbd.2017.09.001

Alonso R, Pisa D, Marina AI, Morato E, Rábano A, et al. 2015. Evidence for fungal infection in cerebrospinal fluid and brain tissue from patients with amyotrophic lateral sclerosis. Int J Biol Sci. 11:546–558. doi:10.7150/ijbs.11084

Andrade FC, Vergetti V, Cozza G, Falcao MC, Azevedo G. 2019. Amyotrophic lateral sclerosis-like syndrome after Chikungunya. Cureus. 11:e5876. doi:10.7759/cureus.5876

Arru G, Mameli G, Deiana GA, Rassu AL, Friedda R, et al. 2018. Humoral immunity response to human endogenous retroviruses K/W differentiates between amyotrophic lateral sclerosis and other neurological diseases. Eur J Neurol. 25:1076-1084. doi:10.1111/ene.13648

Bennett JP, Keeney PM, Brohawn DG. 2019. RNA sequencing reveals small and variable contributions of infectious agents to transcriptionomes of postmortem nervous tissues from amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease subjects, and increased expression of genes from disease-activated microglia. Front Neuosci. 13:235. doi:10.3389/fnins.2019.00235

Berger MM, Kopp N, Vital C, Redl B, Aymard M, et al. 2000. Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology. 54:20-25. doi:10.1212/wnl.54.1.20

Blacher E, Bashiarides S, Shapiro H, Rothschild D, Mor U, et al. 2019. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 572:474–480. doi:10.1038/s41586-019-1443-5

Blasco H, Veyrat-Durebex C, Bocca C, Patin F, Vourc’H P, et al. 2017. Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci Rep. 7:17652. doi:10.1038/s41598-017-17389-9

Blasco H, Corcia P, Moreau C, Veau S, Fournier C, et al. 2010. 1H-NMR-Based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One. 5:e13223. doi:10.1371/journal.pone.0013223

Boni MF, Lemey P, Jiang X, Lam TTY, Perry BW, et al. 2020. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 572:474–480. doi:10.1038/s41586-019-1443-5

Bonf MP, Lemey P, Jiang X, Lam TTY, Perry BW, et al. 2020. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat Microbiol. 5:1408–1417. doi:10.1038/s41556-020-0771-4

Bouquet J, Gardy JL, Brown S, Pfeil J, Miller RR, et al. Complex Chronic Disease Study Group. 2017. RNA-seq analysis of gene expression, viral pathogen, and B-cell/T-cell receptor signatures in complex chronic diseases. Clin Infect Dis. 64:476–481. doi:10.1093/cid/ciw767

Brenner D, Hiergeist A, Adis C, Mayer B, Gessner A, et al. 2013. A fast and robust protocol for metataxonomic analysis using 1H-NMR-Based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One. 5:e13223. doi:10.1371/journal.pone.0013223

Brenner D, Hiergeist A, Adis C, Mayer B, Gessner A, et al. 2013. A fast and robust protocol for metataxonomic analysis using 1H-NMR-Based metabolomic profiling of CSF in early amyotrophic lateral sclerosis. PLoS One. 5:e13223. doi:10.1371/journal.pone.0013223

Castanedo-Vázquez D, Bosque-Varela P, Sainz-Pelayo A, Riancho J. 2019. Infectious agents and amyotrophic lateral sclerosis: another piece of the puzzle of motor neuron degeneration. J Neurol. 266:27–36. doi:10.1007/s00415-018-8919-3

Castillo DJ, Rifkin RF, Cowan DA, Potgieter M. 2019. The healthy human blood microbiome: Fact or fiction? Front Cell Infect Microbiol. 9:148. doi:10.3389/fcimb.2019.00148

Cavadas B, Ferreira J, Camacho R, Fonseca NA, Pereira L. (2017). QmihR: Pipeline for Quantification of Microbiome in Human RNA-Seq. Cham: Springer, p. 173–179. doi:10.1007/978-3-319-60816-7_21

Cermelli C, Vinci B, Pietrini V, Nacci G, et al. 2003. Risk of sporadic amyotrophic lateral sclerosis associated with seropositivity for herpesviruses and echovirus-7. Eur J Epidemiol. 18:123–127. doi:10.1023/A:1020367728557

Coppede F, Stoccoor A, Mosca L, Gallo R, Tarlarini C, et al. 2018. Increase in DNA methylation in patients with amyotrophic lateral sclerosis carriers of not fully penetrant SOD1 mutations. Amyotroph Lateral Scler Frontotemporal Degener. 19:93–101. doi:10.1080/21686421.2017.1367401

Correia AS, Patel P, Dutta K, Julien JP. 2015. Inflammation induces TDP-43 mislocalization and aggregation. PLoS One. 10:e0140248. doi:10.1371/journal.pone.0140248

Cox JW, Ballweg RA, Taft DH, Velayutham P, Haslam DB, et al. 2017. A fast and robust protocol for metataxonomic analysis using RNAseq data. Microbiome. 5:7. doi:10.1186/s41068-016-0192-5

Deutsch SI, Mols RC, Davis KL. 1982. A rationale for studying the transmissibility of Alzheimer’s disease. Neurobiol Aging. 3:145–147. doi:10.1016/0197-4580(82)90011-2

Dovuille R, Liu J, Rothstein J, Nath A. 2011. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol. 69:141–151. doi:10.1002/ana.22149

Emanuel W, Kirstin M, Vedran F, Asija D, Theresa GL, et al. 2020. Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention. BioRxiv. 2020.05.05.079194. doi:10.1101/2020.05.05.079194

Fang X, Wang X, Yang S, Meng F, Wang X, et al. 2016. Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing. Front Microbiol. 7:1479. doi:10.3389/fmicb.2016.01479

Fosso B, Santamaria M, D’Antonio M, Lovero D, Corradu G, et al. 2017. MetaShot: An accurate workflow for taxon classification of host-associated microbiome from shotgun metagenomic data. Bioinformatics. 33:1730–1732. doi:10.1093/bioinformatics/btx036

Frazee AC, Jaffe AE, Langmead B, Leek JT. 2015. Polyester: simulating RNA-seq datasets with differential transcript expression. Bioinformatics. 31:2778–2784. doi:10.1093/bioinformatics/btv272

Gagliardi S, Zucca S, Pandini C, Diamanti L, Bordoni M, et al. 2018. Long non-coding and coding RNAs characterization in peripheral blood mononuclear cells and spinal cord from amyotrophic lateral sclerosis patients. Sci Rep. 8:2378. doi:10.1038/s41598-018-20679-5

Garbuzova-Davis S, Sanberg PR. 2014. Blood-CNS barrier impairment in ALS patients versus an animal model. Front Cell Neurosci. 8:21. doi:10.3389/fncel.2014.00021

Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang YJ, et al. 2017. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci Transl Med. 9:eaa17866. doi:10.1126/scitranslmed.aai7866

Gihawi A, Rallapalli G, Hurst R, Cooper CS, Leggett RM, et al. 2019. SEPATH: benchmarking the search for pathogens in human tissue whose genome sequence data leads to template pipelines. Genome Biol. 20:208. doi:10.1186/s13059-019-1819-8
Ribeiro FJ, Przybylski D, Yin S, Sharpe T, Gnerre S, et al. (2012). Finished bacterial genomes from shotgun sequence data. Genome Res. 22:2270–2277. doi:10.1101/gr.141515.112
Roumpeka DD, Wallace RJ, Escalettes F, Fotheringham I, Watson M. 2017. A review of bioinformatics tools for bio-prospecting from metagenomic sequence data. Front Genet. 8: 23. doi:10.3389/fgene.2017.00023
Shin H, Shannon CP, Fishbane N, Ruan J, Zhou M, et al.; PROOF Centre of Excellence Team. 2014. Variation in RNA-Seq transcriptome profiles of peripheral whole blood from healthy individuals with and without globin depletion. PLoS One. 9:e91041.doi: 10.1371/journal.pone.0091041
Simon LM, Karg S, Westermann AJ, Engel M, Elbehery AHA, et al. 2018. MetaMap: an atlas of metatranscriptomic reads in human disease-related RNA-seq data. GigaScience. 7:gyo070.doi: 10.1093/gigascience/gyo070
Sochocka M, Zwoilińska K, Leszek J. 2017. The infectious etiology of Alzheimer’s disease. Curr Neuropharmacol. 15:996–1009. doi:10.2174/1570159x15666170313122937
Sta M, Sylva-Steenland RMR, Casula M, de Jong JMBV, Troost D, et al. 2011. innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol Dis. 42: 211–220. doi:10.1016/j.nbd.2011.01.002
Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, et al. 2019. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. Eur J Neurol. 26:1355–1361. doi:10.1111/ene.13986
Swindell WR, Kruse CPS, List EO, Berryman DE, Kopchick JJ. 2019. ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia. J Transl Med. 17:170.doi:10.1186/s12967-019-1909-0
Tailbott EO, Malek AM, Lacomis D. 2016. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 138:225–238. doi:10.1016/978-0-12-802973-2.00013-6
Tang X, Toro A, Sahana TG, Gao J, Chalk J, et al. 2020. Divergence, convergence, and therapeutic implications: a cell biology perspective of C9ORF72-ALS/FTD. Mol Neurodegener. 15:34. doi:10.1186/s13024-020-00383-7
Taylor GR, Crow TJ, Markakis DA, Lofthouse R, Neeley S, et al. 1984. Herpes simplex virus and Alzheimer’s disease: a search for virus DNA by spot hybridisation. J Neurol Neurosurg Psychiatry. 47: 1061–1065. doi:10.1136/jnnp.47.10.1061
Trageser KJ, Smith C, Herman FJ, Ono K, Pasinetti GM. 2019. Mechanisms of immune activation by c9orf72-expansions in amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 13:1298.doi: 10.3389/fnins.2019.01298
van Rheenen W, Diekstra FP, Harschmitz O, Westeneng H-J, van Eijk KR, et al. 2018. Whole blood transcriptome analysis in amyotrophic lateral sclerosis: a biomarker study. PLoS One. 13: e0198874.doi:10.1371/journal.pone.0198874
Vandenberghes N, Leveque N, Corcia P, Bruniad-Delan V, Salort-Campana E, et al. 2010. Cerebrospinal fluid detection of enterovirus genome in ALS: a study of 242 patients and 354 controls. Amyotroph Lateral Scler. 11:277–282. doi:10.3109/17482960903262083
Verber NS, Shephard SR, Sassani M, McDonough HE, Moore SA, et al. 2019. Biomarkers in motor neuron disease: a state of the art review. Front Neurol. 10:291.doi: 10.3389/fneur.2019.00291
Verma A, Berger JR. 2006. ALS syndrome in patients with HIV-1 infection. J Neurol Sci. 240:59–64. doi:10.1016/j.jns.2005.09.005
Wallar R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, et al. 2017. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol Aging. 55:123–131. doi:10.1016/j.neurobiolaging.2017.03.027
Wallar R, Wyles M, Heath FR, Kazoka M, Wolliff H, et al. 2018. Small RNA sequencing of sporadic amyotrophic lateral sclerosis cerebrospinal fluid reveals differentially expressed miRNAs related to neural and glial activity. Front Neurosci. 11:731.doi:10.3389/fnins.2017.00731
Westermann AJ, Barquist L, Vogel J. 2017. Resolving host-pathogen interactions by dual RNA-seq. PLoS Pathog. 13:e1006033.doi: 10.1371/journal.ppat.1006033
Wood DE, Salzberg SL. 2014. Kraken: Ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 15:R46.doi:10.1186/gb-2014-15-3-r46
Xue YC, Feurer R, Cashman N, Luo H. 2018. Entero viral infection: the forgotten link to amyotrophic lateral sclerosis? Front Mol Neurosci. 11:63.doi: 10.3389/fnmol.2018.00063
Young PE, Jew SK, Buckland ME, Pamphlett R, Suter CM. 2017. Epigenetic differences between monozygotic twins discordant for amyotrophic lateral sclerosis (ALS) provide clues to disease pathogenesis. PLoS One. 12:e0182638.doi:10.1371/journal.pone.0182638
Zhan Y, Fang F. 2019. Smoking and amyotrophic lateral sclerosis: a mendelian randomization study. Ann Neurol. 85:482–484.doi:10.1002/ana.25443
Zhang R, Miller RG, Gascon R, Champion S, Katz J, et al. 2009. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol. 206:121–124. doi:10.1016/j.jneuroim.2008.09.017
Zhang Y, Guo Wu S, Yi J, Xia Y, Jin D, et al. 2017. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin Ther. 39:322–336.doi:10.1016/j.clinthera.2016.12.014
Zhao S, Zhang Y, Yamini S, Zhang B, von Schack D. 2018. Evaluation of two main RNA-seq approaches for gene quantification in clinical RNA sequencing: polyA+ selection versus rRNA depletion. Sci Rep. 8:4781.doi:10.1038/s41598-018-23226-4
Zucca S, Gagliardi S, Pandini C, Diamanti L, Bordoni M, et al. 2019. RNA-Seq profiling in peripheral blood mononuclear cells of amyotrophic lateral sclerosis patients and controls. Sci Data. 6: 190006.doi:10.1038/sdata.2019.6

Communicating editor: T. Matise